16 Results for "

JH1

" in MedChemExpress (MCE) Product Catalog:
Products (16)

16 Results for "JH1" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-14722
CAS No.: 1092499-93-8
Purity:  99.89%
Target:  

JAK

Research Areas:  

Cancer

NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively [1].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-14722A
CAS No.: 1942919-79-0
Purity:  99.04%
Target:  

JAK

Research Areas:  

Cancer

NVP-BSK805 dihydrochloride is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively [1].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150096
CAS No.: 2272904-53-5
Purity:  98.98%
Synonyms: NDI-034858; TAK-279
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM [1].
loading...
    loading...
Cat. No.: HY-167846
CAS No.: 2417685-83-5
Target:  

JAK

Research Areas:  

Cancer

YLIU-4-105-1 is a Type II JAK2 inhibitor. YLIU-4-105-1 binds to the ATP-binding pocket of JH1. YLIU-4-105-1 has in vivo pharmacodynamic activity as evidenced by inhibiting pSTAT5, reducing spleen to body weight, and lowering blood reticulocyte counts in a dose-dependent manner [1].
loading...
    loading...
Cat. No.: HY-156466
CAS No.: 2848664-42-4
Purity:  99.95%
Research Areas:  

Inflammation/Immunology

QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM,TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) [1].
loading...
    loading...
Cat. No.: HY-E70873
Target:  

JAK

Research Areas:  

Cancer

TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase is a recombinant Tyk2(JH1/JH2) protein that can be used to study Tyk2(JH1/JH2)-related functions [1].
loading...
    loading...
Cat. No.: HY-175983
CAS No.: 3026367-07-4
Target:  

JAK

Research Areas:  

Cancer

JAK1/TYK2-IN-5 (compound A1) is a JAK1/TYK2 inhibitor with Ki values of 0.0044 nM, 0.02 nM, 6.9 μM, 0.79 μM, 0.21 μM and 0.55 μM for TYK2 JH2, JAK1 JH2, JAK1 JH1, JAK2 JH1, JAK3 JH1 and TYK2 JH1, respectiverly. JAK1/TYK2-IN-5 inhibts IFNα induced TYK2/JAK1-mediated STAT activation [1].
loading...
    loading...
Cat. No.: HY-144031S
CAS No.: 2704587-24-4
Purity:  98.04%
Synonyms: Tyk2-IN-8
Fadeucravacitinib (Tyk2-IN-8) is an orally active selective TYK2 inhibitor with an IC50 of 5.7 nM against the JH2 pseudokinase domain. Fadeucravacitinib specifically binds to the TYK2 JH2 domain to exert allosteric inhibition, reduces JH1 kinase activity, and thereby blocks the TYK2/STAT pathway and pro-inflammatory signaling cascades. Fadeucravacitinib can be used in research related to inflammatory bowel disease [1] .
loading...
    loading...
Cat. No.: HY-E70834
Target:  

JAK

Research Areas:  

Cancer

JAK1 is a non-receptor tyrosine kinase that plays a critical role in cell signaling via type I/II cytokines and interferons (IFNs). JAK1(JH1) is a kinase domain. JAK1(JH1) Recombinant Human Active Protein Kinase is a recombinant JAK1(JH1) protein that can be used to study JAK1(JH1)-related functions [1].
loading...
    loading...
Cat. No.: HY-E70836
Target:  

JAK

Research Areas:  

Cancer

JAK3(JH1) is a kinase domain of JAK3. JAK3 is predominantly expressed in haematopoietic cell lineages such as lymphoid cells and mediates receptor-mediated cytokine signalling. JAK3(JH1) Recombinant Human Active Protein Kinase is a recombinant JAK3(JH1) protein that can be used to study JAK3(JH1)-related functions [1].
loading...
    loading...
Cat. No.: HY-E70872
Target:  

JAK

Research Areas:  

Cancer

TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). TYK2(JH1) Recombinant Human Active Protein Kinase is a recombinant TYK2(JH1) protein that can be used to study TYK2(JH1)-related functions [1].
loading...
    loading...
Cat. No.: HY-14722C
CAS No.: 2320258-95-3
Target:  

JAK

Research Areas:  

Cancer

NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively [1].
loading...
    loading...
Cat. No.: HY-E70835
Target:  

JAK

Research Areas:  

Cancer

Janus kinase 2 (JAK2) initiates signaling from several cytokine receptors and is required for biological responses such as erythropoiesis. JAK2 contains the kinase (JH1) and pseudokinase domains (JH2). JAK2(JH1/JH2) Recombinant Human Active Protein Kinase is a recombinant JAK2(JH1/JH2) protein that can be used to study JAK2(JH1/JH2)-related functions [1].
loading...
    loading...
Cat. No.: HY-E70874
Target:  

JAK

Research Areas:  

Cancer

TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). TYK2(JH2) Recombinant Human Active Protein Kinase is a recombinant TYK2(JH2) protein that can be used to study TYK2(JH2)-related functions [1].
loading...
    loading...
Cat. No.: HY-187211
Target:  

JAK

Research Areas:  

Cancer

TYK2 activator-2 (Compound 6g) is a selective TYK2 activator and JAK3 inhibitor, with an EC50 of 0.21 μM against TYK2 and an IC50 of 1.2 μM against JAK3. TYK2 activator-2 destabilizes the JH2-JH1 autoinhibitory complex of TYK2, enhances the catalytic activity of TYK2, and inhibits the JH1 kinase domain activity of JAK3. TYK2 activator-2 can be used in cancer-related research [1].
loading...
    loading...
Cat. No.: HY-P706062
Purity:  ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: JAK2; JAK-2; Janus Kinase 2; Janus Kinase 2 (A Protein Tyrosine Kinase); JTK10; Tyrosine-Protein Kinase; Tyrosine-Protein Kinase JAK2; Janus Kinase
Species:  
Source:  
loading...
    loading...
  • 1